Allos Therapeutics to Present at the Bank of America 2008 Healthcare Conference
06 Mai 2008 - 10:30PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing small molecule
therapeutics for the treatment of cancer, today announced that
members of the Company�s senior management will present a corporate
overview at the Bank of America 2008 Healthcare Conference in Las
Vegas. The Company�s presentation will take place at 8:30 a.m.
(Pacific) on Thursday, May 15, 2008. There will be a live webcast
of the presentation, which will be accessible through a link posted
on the Allos website home page and investor relations section. The
webcast will be available for replay on Allos� website through May
30, 2008. About Allos Therapeutics, Inc. Allos Therapeutics is a
biopharmaceutical company focused on developing and commercializing
small molecule therapeutics for the treatment of cancer.�The
Company's lead product candidate, PDX (pralatrexate), is a novel
antifolate currently under evaluation in a pivotal Phase 2 (PROPEL)
trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The PROPEL trial is being conducted under an agreement
reached with the U.S. Food and Drug Administration under its
special protocol assessment, or SPA, process. The Company is also
investigating PDX in patients with non-small cell lung cancer and a
range of lymphoma sub-types. The Company's other product
candidate�is RH1, a targeted chemotherapeutic agent currently being
evaluated in a Phase 1 trial in patients with advanced solid tumors
or non-Hodgkin�s lymphoma (NHL). For additional information, please
visit the Company�s website at www.allos.com. Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2007 and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
the presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics, Inc.